Lonza says observations made by the FDA at its Texas facility should not further hamper the already delayed approval of Bristol-Myers Squibb’s lymphoma CAR-T candidate liso-cel. Bristol-Myers Squibb (BMS) added lisocabtagene maraleucel (liso-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T‑cell targeting lymphoma, to its pipeline through its $74 billion acquisition of Celgene. Though a Biologics License Application (BLA) was submitted to the US Food and Drug Administration (FDA) in December 2019, COVID-19-related constraints pushed back regulatory inspections necessary for…